Michael Wang
MD
Professor, Department of Lymphoma/Myeloma
👥Biography 个人简介
Michael Wang is a world-leading MCL clinician-researcher who led the ZUMA-2 trial establishing brexucabtagene autoleucel (KTE-X19) for relapsed/refractory MCL after BTK inhibitor failure. He has contributed foundational work on covalent BTK inhibitor therapy and sequencing in MCL. His research spans from early-phase trials to long-term survival analyses in MCL patients.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Wang 的研究动态
Follow Michael Wang's research updates
留下邮箱，当我们发布与 Michael Wang（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment